IRCT20240208060939N1已完成Unknown
Evaluation of the effect of empagliflozin in combination with pioglitazone on fatty liver disease in type 2 diabetic patients referred to Imam Reza hospital during December 2022 to December 2023.
Artesh University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 70 years（—）
- 性别
- All
入选标准
- •Having type 2 diabetes and fatty liver at the same time
排除标准
- •Active or chronic hepatitis, cirrhosis and biliary disease
- •Class III and IV heart failure
- •Renal dysfunction GFR<45
研究者
相似试验
尚未招募
3 期
Effect of Empagliflozin as adjunctive therapy on serum level of oxidative stress biomarkersIRCT20120215009014N486Hamedan University of Medical Sciences80
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
尚未招募
3 期
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
已完成
3 期
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
尚未招募
3 期
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology